Akorn (AKRX) gets FDA approval for a generic version of vancomycin, an antibiotic used against life-threatening infections. It expects to market the drug in the first half of 2009, and sees annual sales of $150M. Shares of the $175M firm are up 28% premarket to $2.50.
Akorn (AKRX) gets FDA approval for a generic version of vancomycin, an antibiotic used against...
From other sites
at CNBC.com (Mar 4, 2015)
at CNBC.com (Jul 15, 2014)
at CNBC.com (Jun 23, 2014)
at CNBC.com (Jan 23, 2014)
at CNBC.com (Aug 27, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs